Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Latest Information Update: 29 Mar 2022
At a glance
- Drugs Everolimus (Primary) ; LCL 161 (Primary) ; Panobinostat (Primary) ; QBM 076 (Primary) ; Siremadlin (Primary) ; Spartalizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 11 Mar 2022 Status changed from active, no longer recruiting to completed.
- 19 Jan 2022 Planned End Date changed from 3 Feb 2022 to 23 Feb 2022.
- 19 Jan 2022 Planned primary completion date changed from 15 Dec 2021 to 23 Feb 2022.